Similarly, the LRRK2 G2019S mutation status did not affect the outcome of STN-DBS in PD patients in a study including 39 Jewish PD patients with bilateral STN-DBS, 13 of whom had the G2019S LRRK2 mutation; this result was also supported by the study of Fernandez et al. [37]. The gene discussed is LRRK2; the disease is Parkinson disease.